Asia Pacific Vulvovaginal Candidiasis Treatment Market Size, 2028

Asia Pacific Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Country and Growth Forecast, 2022 - 2028

Published Date: November-2022 | Number of Pages: 82 | Format: PDF | Report ID: KBV-12754

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Get in-depth analysis of the COVID-19 impact on the Asia Pacific Vulvovaginal Candidiasis Treatment Market

Market Report Description

The Asia Pacific Vulvovaginal Candidiasis Treatment Market would witness market growth of 5.3% CAGR during the forecast period (2022-2028).

The rising awareness regarding VVC in developing nations, as well as the rise in patient inclination towards maintaining genital health, is further raising the demand for vulvovaginal candidiasis treatment. A large proportion of women across the globe have a weak immune system which raises the risk of vulvovaginal candidiasis. Therefore, various market players are increasing investment in research & development activities and clinical trials of drugs.

Getting yeast infections is very common among pregnant women. This happens due to increased estrogen in the body of pregnant women, which may lead to throwing off the normal balance of bacteria and yeast in the vagina, thereby resulting in yeast overgrowth. Most yeast infections during pregnancy often result from the fungus candida Albicans.

The treatment of vulvovaginal candidiasis majorly focuses on suppositories and intravaginal cream. Nowadays, oral fluconazole is majorly used for the treatment of acute vulvovaginal candidiasis. Also, gynecologists prefer pre-intravaginal preparations due to their limited systematic absorption and possible minimal side effects.

Regional nations such as India are among the largest providers of generic drugs. India is a major producer as well as consumer in the pharmaceutical sector. India is among the major exporters of pharmaceutics across more than 200 nations. The rising focus of the government of several regional nations on menstrual hygiene, as well as awareness regarding women's health, is further supporting the expansion of the femtech industry in the Asia region. Considering all these elements, the market for vulvovaginal candidiasis treatment would expand in the region during the projection period.

The China market dominated the Asia Pacific Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $101.5 million by 2028. The Japan market is registering a CAGR of 4.7% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 5.9% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: The Worldwide Vulvovaginal Candidiasis Treatment Market is Projected to reach USD 1.3 Billion by 2028, at a CAGR of 4.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Route of Administration

  • Oral
  • Intravenous
  • Topical

By Drug Class

  • Fluconazole
  • Clotrimazole
  • Terconazole
  • Terbinafine
  • Nystatin
  • Ketoconazole
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Bayer AG
  • Bristol Myers Squibb Company
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
  • Basilea Pharmaceutica Ltd.
  • Scynexis, Inc.
  • Grupo Ferrer Internacional S.A.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global Vulvovaginal Candidiasis Treatment Market Report 2022-2028

North America Vulvovaginal Candidiasis Treatment Market Report 2022-2028

Europe Vulvovaginal Candidiasis Treatment Market Report 2022-2028

LAMEA Vulvovaginal Candidiasis Treatment Market Report 2022-2028

Purchase Report


Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities